{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:17:51Z","timestamp":1784625471229,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM086330"],"award-info":[{"award-number":["T32GM086330"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007148"],"award-info":[{"award-number":["T32HL007148"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01529-w","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:59:59Z","timestamp":1755007199000},"page":"1621-1637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-9219","authenticated-orcid":false,"given":"Tyler C.","family":"Dunlap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-9701","authenticated-orcid":false,"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-9026","authenticated-orcid":false,"given":"Daniel L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7827","authenticated-orcid":false,"given":"Ryan M.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4941-8956","authenticated-orcid":false,"given":"Susanna C.","family":"DeVane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8558-8061","authenticated-orcid":false,"given":"Veronica","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-0877","authenticated-orcid":false,"given":"James M.","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4192-8247","authenticated-orcid":false,"given":"Viet","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Grgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0947-0874","authenticated-orcid":false,"given":"Katarzyna","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7783-0092","authenticated-orcid":false,"given":"Jordan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8542-5768","authenticated-orcid":false,"given":"Jennifer","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-4832","authenticated-orcid":false,"given":"Tejendra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-0990","authenticated-orcid":false,"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-1092","authenticated-orcid":false,"given":"Jonathan S.","family":"Serody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3544-9390","authenticated-orcid":false,"given":"Morgan","family":"Trepte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-2282","authenticated-orcid":false,"given":"Benjamin G.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-2543","authenticated-orcid":false,"given":"William A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-6613","authenticated-orcid":false,"given":"Jonathan R.","family":"Ptachcinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-6790","authenticated-orcid":false,"given":"J. Ryan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-5724","authenticated-orcid":false,"given":"Eric","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-5534","authenticated-orcid":false,"given":"Paul M.","family":"Armistead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-8863","authenticated-orcid":false,"given":"Daniel J.","family":"Crona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","volume":"21","author":"NS Majhail","year":"2015","unstructured":"Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.032.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1529_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27. https:\/\/doi.org\/10.1038\/s41572-023-00438-1.","journal-title":"Nat Rev Dis Prim"},{"key":"1529_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","volume":"37","author":"V Ramachandran","year":"2019","unstructured":"Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin. 2019;37:569\u201382. https:\/\/doi.org\/10.1016\/j.det.2019.05.014.","journal-title":"Dermatol Clin"},{"key":"1529_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.bmt.1701331","volume":"22","author":"P Jacobson","year":"1998","unstructured":"Jacobson P, Uberti J, Davis W, Ratanatharathorn V. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:217\u201325. https:\/\/doi.org\/10.1038\/sj.bmt.1701331.","journal-title":"Bone Marrow Transplant"},{"key":"1529_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/s1083-8791(00)70042-5","volume":"6","author":"D Przepiorka","year":"2000","unstructured":"Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000;6:190\u20137. https:\/\/doi.org\/10.1016\/s1083-8791(00)70042-5.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1529_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.transproceed.2006.12.042","volume":"39","author":"T Mori","year":"2007","unstructured":"Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Transplant Proc. 2007;39:1615\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2006.12.042.","journal-title":"Transplant Proc"},{"key":"1529_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/pgs.10.43","volume":"11","author":"A Capron","year":"2010","unstructured":"Capron A, Mourad M, De Meyer M, De Pauw L, Eddour DC, Latinne D, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703\u201314. https:\/\/doi.org\/10.2217\/pgs.10.43.","journal-title":"Pharmacogenomics"},{"key":"1529_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","volume":"23","author":"X Zuo","year":"2013","unstructured":"Zuo X, Ng CM, Barrett JS, Luo A, Zhang B, Deng C, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23:251\u201361. https:\/\/doi.org\/10.1097\/FPC.0b013e32835fcbb6.","journal-title":"Pharmacogenet Genom"},{"key":"1529_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jcph.1118","volume":"58","author":"O Campagne","year":"2018","unstructured":"Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients. J Clin Pharmacol. 2018;58:1184\u201395. https:\/\/doi.org\/10.1002\/jcph.1118.","journal-title":"J Clin Pharmacol"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/ijms21030858","volume":"21","author":"J Zhu","year":"2020","unstructured":"Zhu J, Patel T, Miller JA, Torrice CD, Aggarwal M, Sketch MR, et al. Influence of germline genetics on tacrolimus pharmacokinetics and pharmacodynamics in allogeneic hematopoietic stem cell transplant patients. Int J Mol Sci. 2020;21:858. https:\/\/doi.org\/10.3390\/ijms21030858.","journal-title":"Int J Mol Sci"},{"key":"1529_CR11","doi-asserted-by":"publisher","first-page":"1334440","DOI":"10.3389\/fphar.2023.1334440","volume":"14","author":"ND Seligson","year":"2023","unstructured":"Seligson ND, Zhang X, Zemanek MC, Johnson JA, VanGundy Z, Wang D, et al. CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation. Front Pharmacol. 2023;14:1334440. https:\/\/doi.org\/10.3389\/fphar.2023.1334440.","journal-title":"Front Pharmacol"},{"key":"1529_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbmt.2011.08.016","volume":"18","author":"R Ram","year":"2012","unstructured":"Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:414\u201322. https:\/\/doi.org\/10.1016\/j.bbmt.2011.08.016.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1529_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/bmt.2015.323","volume":"51","author":"A Ganetsky","year":"2016","unstructured":"Ganetsky A, Shah A, Miano TA, Hwang WT, He J, Loren AW, et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:568\u201372. https:\/\/doi.org\/10.1038\/bmt.2015.323.","journal-title":"Bone Marrow Transplant"},{"key":"1529_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41409-018-0267-5","volume":"54","author":"PA Hagen","year":"2019","unstructured":"Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2\u20133 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant. 2019;54:155\u20138. https:\/\/doi.org\/10.1038\/s41409-018-0267-5.","journal-title":"Bone Marrow Transplant"},{"key":"1529_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/cancers13040613","volume":"13","author":"N Sharma","year":"2021","unstructured":"Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, et al. Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation. Cancers (Basel). 2021;13:613. https:\/\/doi.org\/10.3390\/cancers13040613.","journal-title":"Cancers (Basel)."},{"key":"1529_CR16","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.bbmt.2018.07.029","volume":"24","author":"T Morishita","year":"2018","unstructured":"Morishita T, Okabe M, Kawaguchi Y, Lee Y, Ohbiki M, Osaki M, et al. Higher peak tacrolimus concentrations after allogeneic hematopoietic stem cell transplantation increase the risk of endothelial cell damage complications. Biol Blood Marrow Transplant. 2018;24:2509\u201316. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.029.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1529_CR17","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2215\/CJN.19801220","volume":"16","author":"MH Abramson","year":"2021","unstructured":"Abramson MH, Gutgarts V, Zheng J, Maloy MA, Ruiz JD, Scordo M, et al. Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation. Clin J Am Soc Nephrol. 2021;16:1318\u201327. https:\/\/doi.org\/10.2215\/CJN.19801220.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1529_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41409-021-01528-y","volume":"57","author":"JM Yao","year":"2022","unstructured":"Yao JM, Yang D, Clark MC, Otoukesh S, Cao T, Ali H, et al. Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplant. 2022;57:232\u201342. https:\/\/doi.org\/10.1038\/s41409-021-01528-y.","journal-title":"Bone Marrow Transplant"},{"key":"1529_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2011.06.008","volume":"18","author":"T Mori","year":"2012","unstructured":"Mori T, Kato J, Shimizu T, Aisa Y, Nakazato T, Yamane A, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2012;18:229\u201334. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.008.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1529_CR20","unstructured":"Prograf (tacrolimus) [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2023."},{"key":"1529_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/cts.12956","volume":"14","author":"J Zhu","year":"2021","unstructured":"Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, et al. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clin Transl Sci. 2021;14:908\u201318. https:\/\/doi.org\/10.1111\/cts.12956.","journal-title":"Clin Transl Sci"},{"key":"1529_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2023.e00322","volume":"36","author":"RD Maynard","year":"2023","unstructured":"Maynard RD, Bates P, Korpi-Steiner N. Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient. Pract Lab Med. 2023;36: e00322. https:\/\/doi.org\/10.1016\/j.plabm.2023.e00322.","journal-title":"Pract Lab Med."},{"key":"1529_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19\u201324. https:\/\/doi.org\/10.1002\/cpt.113.","journal-title":"Clin Pharmacol Ther"},{"key":"1529_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2017","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215\u201323. https:\/\/doi.org\/10.1038\/gim.2016.87.","journal-title":"Genet Med"},{"key":"1529_CR25","unstructured":"R Core Team R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. https:\/\/www.R-project.org\/. Cited 5 Nov 2024."},{"key":"1529_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/psp4.13115","volume":"13","author":"K Sanghavi","year":"2024","unstructured":"Sanghavi K, Ribbing J, Rogers JA, Ahmed MA, Karlsson MO, Holford N, et al. Covariate modeling in pharmacometrics: general points for consideration. CPT Pharmacomet Syst Pharmacol. 2024;13:710\u201328. https:\/\/doi.org\/10.1002\/psp4.13115.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1529_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.bmt.1703224","volume":"28","author":"P Jacobson","year":"2001","unstructured":"Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001;28:753\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1703224.","journal-title":"Bone Marrow Transplant"},{"key":"1529_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/FTD.0b013e31829da6dd","volume":"36","author":"L Elens","year":"2014","unstructured":"Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014;36:71\u20139. https:\/\/doi.org\/10.1097\/FTD.0b013e31829da6dd.","journal-title":"Ther Drug Monit"},{"key":"1529_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Midtvedt K, Bremer S, Bergan S, \u00c5sberg A. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70:65\u201377. https:\/\/doi.org\/10.1007\/s00228-013-1584-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"1529_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet. 2020;59:1357\u201392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x.","journal-title":"Clin Pharmacokinet"},{"key":"1529_CR31","unstructured":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014General Considerations (FDA Guidance Document No. 71) [Internet]. U.S. Food and Drug Administration. 2003. https:\/\/www.ipqpubs.com\/wp-content\/uploads\/2020\/12\/BioStudies_OralDosageProducts_March.2003.GUIDANCE.pdf.pdf. Cited 15 Mar 2024."},{"key":"1529_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Progr Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Progr Biomed"},{"key":"1529_CR33","unstructured":"Baron KT. mrgsolve: simulate from ODE-based models. R package version 1.0.6 [Internet]. 2023. https:\/\/github.com\/metrumresearchgroup\/mrgsolve. Cited 25 Apr 2024."},{"key":"1529_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s002280100331","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57:479\u201384. https:\/\/doi.org\/10.1007\/s002280100331.","journal-title":"Eur J Clin Pharmacol"},{"key":"1529_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","volume":"51","author":"C Monchaud","year":"2012","unstructured":"Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, et al. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51:175\u201386. https:\/\/doi.org\/10.2165\/11594760-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1529_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJAR Moes","year":"2016","unstructured":"Moes DJAR, van der Bent SAS, Swen JJ, van der Straaten T, Inderson A, Olofsen E, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72:163\u201374. https:\/\/doi.org\/10.1007\/s00228-015-1963-3.","journal-title":"Eur J Clin Pharmacol"},{"key":"1529_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/pgs-2018-0116","volume":"20","author":"Y Han","year":"2019","unstructured":"Han Y, Zhou H, Cai J, Huang J, Zhang J, Shi S-J, et al. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics. 2019;20:21\u201335. https:\/\/doi.org\/10.2217\/pgs-2018-0116.","journal-title":"Pharmacogenomics"},{"key":"1529_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85:601\u201315. https:\/\/doi.org\/10.1111\/bcp.13838.","journal-title":"Br J Clin Pharmacol"},{"key":"1529_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13318-022-00767-8","volume":"47","author":"LG Franken","year":"2022","unstructured":"Franken LG, Francke MI, Andrews LM, van Schaik RHN, Li Y, de Wit LEA, et al. A population pharmacokinetic model of whole-blood and intracellular tacrolimus in kidney transplant recipients. Eur J Drug Metab Pharmacokinet. 2022;47:523\u201335. https:\/\/doi.org\/10.1007\/s13318-022-00767-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1529_CR40","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1111\/bcp.15857","volume":"89","author":"A Paschier","year":"2023","unstructured":"Paschier A, Destere A, Monchaud C, Labriffe M, Marquet P, Woillard J-B. Tacrolimus population pharmacokinetics in adult heart transplant patients. Br J Clin Pharmacol. 2023;89:3584\u201395. https:\/\/doi.org\/10.1111\/bcp.15857.","journal-title":"Br J Clin Pharmacol"},{"key":"1529_CR41","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"key":"1529_CR42","doi-asserted-by":"publisher","unstructured":"Jansen SA, Cutilli A, de Koning C, van Hoesel M, Frederiks CL, Saiz Sierra L, et al. Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T\u00a0cell behavior. iScience. 2024;27:110072. https:\/\/doi.org\/10.1038\/s41385-022-00527-6.","DOI":"10.1038\/s41385-022-00527-6"},{"key":"1529_CR43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41385-022-00527-6","volume":"15","author":"SA Jansen","year":"2022","unstructured":"Jansen SA, Nieuwenhuis EES, Hanash AM, Lindemans CA. Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease. Mucosal Immunol. 2022;15:605\u201319. https:\/\/doi.org\/10.1038\/s41385-022-00527-6.","journal-title":"Mucosal Immunol"},{"key":"1529_CR44","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1172\/JCI98554","volume":"129","author":"SC Nalle","year":"2019","unstructured":"Nalle SC, Zuo L, Ong MLDM, Singh G, Worthylake AM, Choi W, et al. Graft-versus-host disease propagation depends on increased intestinal epithelial tight junction permeability. J Clin Invest. 2019;129:902\u201314. https:\/\/doi.org\/10.1172\/JCI98554.","journal-title":"J Clin Invest"},{"key":"1529_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/cr.2017.54","volume":"27","author":"Q Lian","year":"2017","unstructured":"Lian Q, Xu J, Yan S, Huang M, Ding H, Sun X, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017;27:784\u2013800. https:\/\/doi.org\/10.1038\/cr.2017.54.","journal-title":"Cell Res"},{"key":"1529_CR46","unstructured":"Project Optimus. Oncology Center of Excellence. U.S. Food and Drug Administration. [Internet]. 2024 [cited 2024 Sep 1]. Available from: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus."},{"key":"1529_CR47","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2215943.","journal-title":"N Engl J Med"},{"key":"1529_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404\u201330. https:\/\/doi.org\/10.2165\/00003088-199529060-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1529_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1529_CR50","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02895.x","volume":"64","author":"M Antignac","year":"2007","unstructured":"Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64:750\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02895.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1529_CR51","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM. CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag. 2018;14:2119\u201326. https:\/\/doi.org\/10.2147\/TCRM.S184376.","journal-title":"Ther Clin Risk Manag"},{"key":"1529_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1056-8719(02)00158-2","volume":"46","author":"H Zahir","year":"2001","unstructured":"Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27\u201335. https:\/\/doi.org\/10.1016\/s1056-8719(02)00158-2.","journal-title":"J Pharmacol Toxicol Methods"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01529-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01529-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01529-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:34Z","timestamp":1763168614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01529-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01529-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"14 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Dunlap was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM086330. Dr. Zhu was supported by the NHLBI under award number T32HL007148. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Weiner is an independent member of the Board of Directors and a member of the Scientific Advisory Board for Simulations Plus (Nasdaq:SLP). All other authors report no conflicts of interest related to this research. At the time of study conception and execution, Dr. Dunlap, Dr. Zhu, Dr. DeVane, Dr. Nguyen, Dr. Patel, Dr. Riches, and Dr. Ptachcinski were all employed at the University of North Carolina. However, currently Dr. Dunlap is employed by Metrum Research Group, Dr. Zhu by Pfizer, Dr. DeVane by Immatics, Dr. Nguyen by Biogen, Dr. Patel by Bristol Myers Squibb, Dr. Riches by Kura Oncology, and Dr. Ptachcinski by Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All research activities were performed in accordance with the ethical standards of the responsible committee on human experimentation or with the Helsinki Declaration of 1975. Both studies =received approval from the University of North Carolina Institutional Review Board (UNC IRB) prior to subject enrollment and data collection (UNC16-1480 and UNC19-3328). UNC16-1480 was originally approved on July 21, 2016, and UNC19-3328 was originally approved on June 16, 2020. Both studies were renewed in 2025 by the UNC IRB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All research subjects from both studies (UNC16-1480 and UNC19-3328) provided informed consent to participate in their respective studies, for their genetic material to be used in our pharmacogenetics experiments and in the pharmacometric modeling and simulation, and all subjects provided consent to publish study results.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Deidentified individual data that supports the results will be shared beginning 9\u201336 months following publication, provided the investigator who proposes to use the data has approval from an institutional review board (IRB), independent ethics committee (IEC), or research ethics board (REB), as applicable, and executes a data use\/sharing agreement with UNC.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing Statement"}},{"value":"Designed research\u2014T.C.D., D.Z., J.R.P., P.M.A., D.L.W., and D.J.C. Performed research\u2014all authors. Analyzed data\u2014T.C.D., D.Z., D.L.W., R.M.K., and D.J.C. Wrote manuscript\u2014all authors. Approved content for publication\u2014all authors. Contributed new reagents\/analytical tools\u2014NA.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"NONMEM control stream is in the supplemental.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}